Dow Jones

51 019,22

0,30%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Etats-Unis
AMEX
Dor Biopharma (DOR)
Dor Biopharma (DOR) Actualités

Dor Biopharma (DOR)

0,00

( 0,00% )

Mis à jour : -

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin; Antigens are Made Using Dowpharma's Pfenex Expression

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today the first successful evaluation in animal tests of a nasal, bivalent...

DOR BioPharma Announces Private Equity Financing of $3.65 Million with Institutional Investors

DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR) announced that it has entered into definitive agreements for the sale of securities in a...

DOR BioPharma Reports Year End 2005 Financial Results and Accomplishments; DOR Provides Guidance on Regulatory Filings on orBec

DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company") announced today its financial results for 2005. ? Revenues for 2005 were $3,075,736...

DOR BioPharma Provides Financial Guidance and Update on European Regulatory Plans for orBec(R)

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today that it is focusing its resources on the preparation of New Drug...

DOR BioPharma Announces Positive Phase I Results of RiVax(TM), its Vaccine Against Ricin Toxin; Vaccine is Immunogenic and Well

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") today announced results of a Phase I clinical trial of RiVax(TM), a recombinant vaccine...

DOR BioPharma Achieves Manufacturing Milestone in Development of RiVax(TM); DOR and Its Collaborators Achieve 2nd Milestone Ahea

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") today announced that it has successfully completed the second development milestone for...

DOR BioPharma Reports Positive New Survival Findings from Previously Completed Phase II and III Clinical Trials of orBec(R); Res

DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today that as part of its process to submit a New Drug Application ("NDA") for...

DOR BioPharma Secures $6 Million Equity Commitment from Fusion Capital

DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR), today announced that it has entered into a common stock purchase agreement with Fusion...

DOR BioPharma Plans FDA NDA and European MAA Filing Strategy for orBec

DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company"), announced today that following written communications and meetings with the FDA and with...

DOR BioPharma Inc. Reports Third Quarter 2005 Financial Results and Reviews Recent Achievements; Conference Call Scheduled for N

DOR BioPharma Inc. (AMEX: DOR) ("DOR" or the "company") announced today its financial results for the third quarter ended Sept. 30, 2005. The...

DOR BioPharma to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the "Company"), announced today that Evan Myrianthopoulos, Chief Financial Officer of DOR, will be...

DOR BioPharma Executes Letter of Intent for Acquisition of Gastrotech Pharma; Acquisition Bolsters Biotherapeutics Pipeline

DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the "Company"), announced today that it has signed a binding letter of intent to acquire Gastrotech...

DOR BioPharma Receives Notice of Delisting from American Stock Exchange; Company to Continue to Negotiate Potential Compliance-A

DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the "Company"), announced today that it has received notice from the American Stock Exchange (the...

DOR BioPharma Provides Update on Programs and Corporate Matters

DOR BioPharma, Inc. (AMEX:DOR) ("DOR" or the "Company"), today provided a general update on various corporate matters. ? orBec(R) IND Transferred...

Dr. Chris Dale, Vice President, Technology, Cambrex Biopharmaceuticals and Dr. Robert N. Brey, Chief Scientific Officer, DOR Bio

EAST RUTHERFORD, N.J. and MIAMI, Sept. 15 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE:CBM) and DOR BioPharma, Inc. (AMEX:DOR) are...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

L&G Japan Equity UCITS E...

Euronext G Credit Agrico...

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Dor Biopharma (DOR)

Outils de qualité professionnelle, pour des investisseurs individuels.